Phase 2/3 RCT: Tocilizumab in patients with new onset polymyalgia rheumatica reduces flares in a protocol of rapid glucocorticoid tapering (from 20 mg to 0 mg over 11 weeks).
13 May, 2022 | 10:42h | UTCTocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised controlled trial – Annals of Rheumatic Diseases (link to abstract – $ for full-text)